Trial

NCT02220738

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
AbbVie
Collaborators
Condition
Alzheimer's Disease
Intervention
ABT-957
Why stopped
Slow subject enrollment
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-07-06